

## Staphylococcus intermedius infections: case report and literature review

Nancy Wang,<sup>1,2</sup> Anne M. Neilan,<sup>3</sup>  
Michael Klompas<sup>1,3,4,5,6</sup>

<sup>1</sup>Department of Neurology, Brigham and Women's Hospital, Boston, MA;

<sup>2</sup>Department of Neurology, Massachusetts General Hospital, MA;

<sup>3</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA;

<sup>4</sup>Department of Infectious Diseases, Massachusetts General Hospital Boston, MA; <sup>5</sup>Infection Control Department, Brigham and Women's Hospital, Boston, MA; <sup>6</sup>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

### Abstract

*Staphylococcus intermedius* is part of the normal skin and oral flora of dogs. Case reports of human infections are rare, but the true incidence is unknown because the pathogen is frequently misidentified as *Staphylococcus aureus*. Reported cases range from soft tissue infections to brain abscess. Most reported cases in humans have been related to dog exposure. We report a case of a 73 year old female with *S. intermedius* surgical wound infection one month following a left elbow total arthroplasty. This is the first reported human case of *S. intermedius* infection of a mechanical prosthesis. The presumed source of infection was the patient's dog. The patient was treated with vancomycin, then switched to cefazolin and rifampin once susceptibilities were known. Case reports suggest that patients generally respond well to tailored antibiotics with complete or near-complete recovery. *S. intermedius* should be included in the differential diagnosis of invasive infection amongst patients with close contact with dogs.

### Introduction

*Staphylococcus intermedius* was first described in 1976 as a coagulase-positive Staphylococcus. It has since been identified as part of normal skin and mucosal flora in a variety of animals, including dogs, cats, pigeons, minks, horses, foxes, raccoons, goats, and gray squirrels.<sup>1</sup> It is the predominant cause of skin and soft tissue infection in dogs,<sup>2-6</sup> but has only

rarely been isolated from humans. However, there are an increasing number of case reports documenting serious invasive infections with *S. intermedius* in humans including infected dog bite wounds,<sup>4,7-11</sup> bacteremia,<sup>1</sup> pneumonia,<sup>12</sup> sinusitis,<sup>13</sup> otitis externa,<sup>14</sup> nail bed infection,<sup>15</sup> mastoiditis,<sup>16</sup> brain abscess,<sup>17</sup> skin abscess,<sup>18</sup> and bacteremia complicated by septic arthritis and iliacus abscess.<sup>19</sup> There has also been one reported outbreak of *S. intermedius* related food intoxication involving over 265 cases in the western United States in 1991.<sup>20</sup> More recently, the discovery of *Staphylococcus pseudintermedius* in 2005 has led to the reclassification of isolates formerly identified as *S. intermedius* based on molecular techniques.<sup>21</sup> The *S. intermedius* group (SIG) was divided into *S. intermedius*, *S. pseudintermedius*, and *Staphylococcus delphini*.<sup>22</sup> According to this new grouping, *S. pseudintermedius*, and not *S. intermedius*, is the species that colonizes and causes infections in dogs and cats, and *S. intermedius* mainly colonizes pigeons.<sup>22,23</sup> Thus, older reports of *S. intermedius*, particularly in animal bites, are often now viewed as *S. pseudintermedius*.<sup>24</sup>

Because human infection with coagulase positive Staphylococci other than *S. aureus* is rare, pitfalls in identification of SIG organisms abound. The true incidence of SIG infections is unknown but likely higher than reported since laboratories tend to presumptively identify coagulase-positive Staphylococci as *S. aureus*.<sup>1</sup> Additionally, *S. intermedius* has been falsely identified as MRSA on the basis of the phenotypic PB2 latex agglutination test which has otherwise good performance for detection of methicillin resistant *S. aureus* and coagulase negative Staphylococci.<sup>15</sup> Talan *et al.* found that 100% of *S. aureus* isolates were coagulase positive at 4 hours compared to only 26% of *S. intermedius* isolates.<sup>4</sup> Thus, microbiology personnel should suspect SIG when coagulase tests proceed more slowly than normal and there is high clinical suspicion, such as history of an animal bite. The presence of SIG can then be confirmed through additional biochemical tests: SIG is pyrrolidonyl arylamidase and  $\beta$ -galactosidase positive in contrast to *S. aureus*.<sup>4,25</sup> More recently, Sasaki *et al.* found that *S. intermedius* can be chemically distinguished from *S. pseudintermedius* by positive arginine dihydrolase and acid production from beta-gentiobiose and D-mannitol.<sup>22</sup> The two species can also be distinguished using molecular and genetic testing, as well as MALDI-TOF mass spectrometry, although this is not commonly done.<sup>24,26</sup>

### Case Report

A 73 year old Caucasian female with a history of severe osteoarthritis developed fever, pain,

Correspondence: Nancy Wang, Department of Neurology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA.  
Tel. +1.617.7327432 - Fax: +1.617.7326083.  
E-mail: nwang6@partners.org

Key words: *Staphylococcus intermedius*, pseudintermedius, infection, human.

Conflict of interests: the authors declare no potential conflict of interests.

Received for publication: 1 July 2012.

Revision received: 25 August 2012.

Accepted for publication: 18 October 2012.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright . Wang *et al.*, 2013  
Licensee PAGEPress, Italy  
*Infectious Disease Reports* 2013; 5:e3  
doi:10.4081/idr.2013.e3

redness, and swelling of her left elbow one month following a revision left elbow total arthroplasty. The original arthroplasty 10 years earlier had been complicated by infection that was successfully treated with several weeks of intravenous antibiotics according to the patient; the details of this remote infection and treatment were unattainable. She was subsequently well for many years without antibiotics until about 2 years prior to presentation when she began to develop gradually progressive joint instability and pain. She was admitted for elective total arthroplasty of the left elbow. Following surgery, she noted continuous serosanguinous drainage. Her orthopedist aspirated the joint on post-operative day 22. The joint fluid was described as cloudy with 26,000 red blood cells, 1300 white blood cells and 31% neutrophils. No organisms were seen on Gram stain, and bacterial cultures were negative. Patient was not started on antibiotics at this time. A few days later (post-operative day 25) she developed progressive elbow pain and fever and was admitted to the hospital. On admission, her temperature was 102.2°F and her white blood cell count was 11,000 cells/mm<sup>3</sup>.

On surgical exploration, a large fluid collection was found in the elbow. The joint capsule appeared intact, however both wound and joint fluid cultures grew *S. intermedius*, as identified by the Vitek II automated microbiology system without further subspeciation. The wound was irrigated but the elbow prosthesis was not removed. Blood cultures were negative. In accordance with CLSI standards, the elbow isolates were determined to be resistant to penicillin and tetracycline but susceptible to oxacillin, erythromycin, clindamycin, chloram-

**Table 1. Staphylococcus intermedius group infections in humans.**

| Author, year      | Infection site                                | Age sex | Presentation  | Predisposing factors   | Pet exposure                             | Treatment*   | Resistance                        | Sensitivity   | Initially misidentified?                            | Recovery                               |
|-------------------|---|---------|---|--|--|--|-----------------------------------|---|---|--|
| Atalay, 2005      | Brain abscess                                 | 4M      | Fever, nausea, vomiting, headache, lethargic, R hemiparesis | None   | Unknown                                  | IV vancomycin x8wks  | PCN, MET, CLI, SAM                | NR  | N   | Partial (minimal residual hemiparesis) |
| Barnham, 1992     | Hand wound                                    | 78M     | Pain, discharge, inflammation                               | None   | Y (dog bite)                             | Amoxicillin-clavulanate  | PCN, TET                          | AMC, FUS, ERY, FLU, GEN   | N   | Complete                               |
| Chuang, 2010*     | Catheter-related bacteremia                   | 6M      | Erythema, catheter site tenderness, fever                   | Hemophilia B   | Y (dog owner)                            | Oxacillin 100 mg/kg/day x18d   | PCN, COL                          | VAN, OXA, CIP   | Y ( <i>S. aureus</i> , then <i>S. intermedius</i> ) | Complete                               |
| Gerstadt, 1999    | Pneumonia                                     | 73M     | POD5 s/p CABG, fever, increased secretions                  | NIDDM  | N  | Vancomycin   | PCN, OXA, CFZ, CTX, CLI, ERY, OFX | SXT, GEN, VAN   | N   | Complete                               |
| Hatch, 2012       | Bacteremia, septic arthritis, iliacus abscess | 76M     | Fever, rash   | NIDDM, MDS   | Y (dog owner)                            | Vancomycin x52d  | NR                                | VAN   | N   | NR                                     |
| Kelesidis, 2010   | Forearm abscesses                             | 43M     | Chills  | HCV, intravenous drug use  | N  | Amoxicillin-clavulanate PO x2wks   | NR                                | OXA, SAM, CFZ, LVX CLI, DOX, GEN, SXT, VAN                      | N   | Complete                               |
| Kempker, 2009     | Sinusitis                                     | 28F     | Foul-smelling nasal discharge, mild headache                | 8 mo s/p transphenoidal resection of pituitary adenoma, CSF leak, diabetes insipidus, anemia | Y (dog with recent pyoderma licked face) | Bilateral sphenoidotomy, IV vancomycin, then PO linezolid to complete 6wk course | CFZ, LVX, OXA, SXT, TET           | NR  | Y (CoNS, then MRSA)                                 | Complete                               |
| Kikuchi, 2004     | Mastoiditis                                   | 51F     | Irritation, otorrhea  | Chronic otitis media with cholesteatoma, 7 yrs s/p mastoidectomy                             | Y (dog licked ear)                       | Oфлоxacin ear drops  | NR                                | PCN, OXA, CFZ, GEN, ERY, CLI, MIN, VAN, LVX, SXT                | Y ( <i>S. aureus</i> )                              | Complete                               |
| Lee, 1994         |   | NR      | NR  | NR   | Y (dog bite)                             | NR   | NR                                | NR  | N   | NR                                     |
|                   |   | NR      | NR  | NR   | Y (dog bite)                             | NR   | NR                                | NR  | N   | NR                                     |
|                   |   | NR      | NR  | NR   | Y (dog bite)                             | NR   | NR                                | NR  | N   | NR                                     |
|                   |   | NR      | NR  | NR   | Y (dog bite)                             | NR   | NR                                | NR  | N   | NR                                     |
|                   |   | NR      | NR  | NR   | Y (dog bite)                             | NR   | NR                                | NR  | N   | NR                                     |
|                   |   | NR      | NR  | NR   | Y (dog bite)                             | NR   | NR                                | NR  | N   | NR                                     |
|                   | Leg ulcer                                     | NR      | NR  | Varicose ulcer   | Y (dog owner)                            | NR   | NR                                | NR  | N   | NR                                     |
|                   | Leg ulcer                                     | NR      | NR  | Varicose ulcer   | Y (dog owner)                            | NR   | NR                                | NR  | N   | NR                                     |
|                   | Infected suture line                          | I3      | NR  | NR   | Y (dog contact)                          | NR   | NR                                | NR  | N   | NR                                     |
| Pottumarthy, 2004 | Nail bed infection                            | 60F     | Inflamed nail bed, greenish discoloration                   | Breast cancer undergoing chemotherapy  | Unknown                                  | NR   | PCN                               | OXA, SAM, AMC, CFZ, CIP, LVX, ERY, CLI, GEN, NIT, TET, SXT, VAN | Y (MRSA)  | NR                                     |
|                   | Leg laceration                                | 37M     | Cellulites, non-healing wound with foul discharge           | None   | Unknown                                  | NR   | PCN, TET                          | OXA, SAM, AMC, CFZ, CIP, LVX, ERY, CLI, GEN, NIT, SXT, VAN      | Y (MRSA)  | NR                                     |
| Riegel, 2011*     | ICD-related endocarditis                      | 70F     | Purulent drainage, fever                                    | None   | Y (dog exposure)                         | Cloxacillin 2g Q4hrs 6wks, gentamicin 240 mg Qday x5d                            | ERY, AMK                          | MET, GEN, CIP, RIF, VAN   | Y ( <i>S. intermedius</i> )                         | Complete                               |

To be continued on next page

Table 1. Continued from previous page.

| Author, year     | Infection site              | Age sex | Presentation                     | Predisposing factors   | Pet exposure              | Treatment <sup>o</sup>  | Resistance  | Sensitivity  | Initially misidentified? | Recovery |
|------------------|-----------------------------|---------|----------------------------------|--|---------------------------|---|---|--|--------------------------|----------|
| Stegmann, 2010*  | Surgical wound              | NR, M   | Purulent drainage                | 5wks s/p sinus surgery for R frontal sinus mucocele, b/o recurrent sinusitis | Y (dog, cat, horse owner) | Fusidic acid gauze + 2% mupirocin ointment QID x3d, topical packing (0.5 mg/g fluocinonide, 2.5 mg/g neomycin, 0.25 mg/g gramicidin, 100,000 IU/g nystatin) x4d | AMC, CEF, CLI, ENR, ERY, GEN, KAN, MUP, OXA, PCN, STR, TET, SXT | AMK, CHL, FUS, LZD, NIT, RIF, VAN, QDA                               | N                        | Complete |
| Talan, 1989      | Hand wound                  | 45M     | Pain, swelling, erythema         | None   | Y (dog bite)              | Amoxicillin-clavulanate 500mg PO TID x10d   | PCN   | OXA, SAM, AMC, CFZ, CIP, LVX, ERY, CLI, GEN, NIT, TET, SXT, VAN      | Y ( <i>S. aureus</i> )   | Complete |
|                  | Hand, thigh, forearm wounds | 20M     | Pain, swelling, erythema         | None   | Y (dog bite)              | Penicillin V 500 mg PO QID x5d  | NR  | PCN  | Y ( <i>S. aureus</i> )   | Complete |
|                  | Forearm wound               | 34F     | Pain, erythema, exudate          | None   | Y (dog bite)              | Penicillin V 250 mg PO QID x5d  | NR  | PCN  | Y ( <i>S. aureus</i> )   | Complete |
| Talan, 1999      | Wound                       | NR      | NR                               | NR   | Y (dog bite)              | NR  | NR  | NR   | Y ( <i>S. aureus</i> )   | NR       |
|                  | Wound                       | NR      | NR                               | NR   | Y (cat bite)              | NR  | NR  | NR   | N                        | NR       |
| Tanner, 2000     | Otitis externa              | 38F     | NR                               | None   | Y (dog owner)             | Topical neomycin, polymyxin B   | NR  | NR   | N                        | Complete |
| Vandenesch, 1995 | Bacteremia                  | 63M     | Inflammation at line site, fever | Metastatic NSC lung carcinoma s/p splenectomy, chemotherapy                  | Y (cat owner)             | Amoxicillin-clavulanate 1gm PO Q8hrs, ciprofloxacin 200mg PO Q12hrs x10d  | DOX   | PCN, OXA, GEN, KAN, CHL, ERY, LCM, PRI, RIF, SXT, PEF, FOF, VAN, TEC | N                        | Complete |
| Van Hoovels*     | ICD pocket infection        | 60M     | Pocket perforation               | Ischemic cardiomyopathy, prostate cancer                                     | Unknown                   | Flucloxacillin 500 mg PO QID x1wk   | PCN, CLI, ERY   | OXA  | Y ( <i>S. aureus</i> )   | NR       |
| This report      | Elbow wound                 | 73F     | Pain, erythema, swelling, fever  | 1 mo s/p revision L elbow arthroplasty                                       | Y (dog owner)             | Cefazolin 2gm IV Q24hrs, rifampin 300mg PO Q12hrs x4wks   | PCN, TET  | OXA, ERY, CLI, CHL, GEN, RIF, LVX, LZD, VAN                          | N                        | Complete |

NR, not reported; PCN, penicillin; MET, methicillin; CLI, clindamycin; SAM, ampicillin sulbactam; AMC, amoxicillin clavulanate; TET, tetracycline; FUS, fusidic acid; ERY, erythromycin; FLU, fluocloxacillin; GEN, gentamicin; COL, colistin; OXA, oxacillin; CFZ, ceftazolin; CFX, ceftaxime; OFX, ofloxacin; LVX, levofloxacin; DOX, doxycycline; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin; MIN, minocycline; CIP, ciprofloxacin; NIT, nitrofurantoin; DOX, doxycycline; AMK, amikacin; KAN, kanamycin; LCM, lincosamide; PRI, pristinamycin; PEF, pefloxacin; FOF, fosfomicin; TEC, teicoplanin; CHL, chloramphenicol; RIF, rifampin; LZD, linezolid; CEF, cefalotin; ENR, enrofloxacin; MUP, mupirocin; STR, streptomycin; QDA, quinupristin/dalopristin; MVA, motor vehicle accident; HIV, human immunodeficiency virus; POD, postoperative day; CABG, coronary artery bypass graft; s/p, status post; NIDDM, non-insulin dependent diabetes mellitus; HCX, Hepatitis C virus; MDS, myelodysplastic syndrome; CoNS, coagulase negative *Staphylococcus aureus*; NSC, non small cell. \**Staphylococcus pseudintermedius* infection. <sup>o</sup>Duration not specified unless otherwise noted. See reference list.

phenicol, gentamicin, rifampin, levofloxacin, linezolid, and vancomycin. The patient was treated with intravenous cefazolin and rifampin for six weeks and then transitioned to oral levofloxacin and rifampin with plan for a prolonged course given retention of infected prosthesis. She has not had any recrudescence of disease after 10 months on this regimen and will be reevaluated for possible cessation of therapy at one year's time.

The patient was an avid dog lover. Although she did not recall her dog licking or biting her elbow after surgery, she did report that her dog frequently licked her face. She admitted to frequent close contact with her dog including sharing her bed at night. She denied any recent illness or skin lesions in her dog.

## Discussion

Human SIG infections are rarely reported. We conducted a literature review by searching PubMed using the terms *Staphylococcus intermedius*, *S. intermedius*, *Staphylococcus delphini*, *Staphylococcus pseudintermedius*, infection and human. References cited in these articles were also examined. Only articles published in English were reviewed, and only invasive infections were included in this discussion. The documented outbreak of *S. intermedius* related food-borne illness was excluded as additional clinical information on the individual cases was not available.

We found 17 published articles documenting 29 SIG infections in humans, 25 with *S. intermedius* and 4 with *S. pseudintermedius*. There were no published cases of *S. delphini* in humans. All 29 cases are outlined in Table 1, with asterisks marking cases of *S. pseudintermedius*. Notably, *S. intermedius* and *S. pseudintermedius* were initially misidentified as *S. aureus* in 34% of 29 cases. Seven of 29 cases (24%) were reported to be polymicrobial by Gram stain, culture, or PCR restriction fragment length polymorphism. Four of the seven polymicrobial cases occurred in dog bite wounds, and one occurred in a patient with known dog exposure.

*S. intermedius* was first described as a human pathogen in dog bite wounds by Talan in 1989.<sup>4</sup> Overall, 23 of the 29 (79%) of reported cases involved dog bites (11 cases), cat bites (one case), or dog or cat exposure without documented bites (11 cases).<sup>8-11,19,27-29</sup> The rate of *S. intermedius* infection in dog bite infection case series ranged from two to 21%.<sup>10,11</sup> Three of the 11 cases in patients without documented bites but with dog or cat exposure were delayed surgical site infections: one case of sinusitis eight months after a transsphenoidal resection of a pituitary adenoma, one case of mastoiditis seven years after a

mastoidectomy, and one case of a surgical wound infection five weeks after sinus surgery.<sup>13,16,27</sup> These cases suggest that alteration of local host defenses may be a risk factor for inoculation without a bite.

Six of the 29 cases (21%) in this series occurred in patients without known animal exposures suggesting that humans can carry this organism in the absence of animal pressure.<sup>12,15,17,18,30</sup> In one case, an intravenous cocaine user accustomed to licking his syringe prior to injection developed skin abscesses.<sup>18</sup> Notably, screening series have variously found

*S. intermedius* in five of 56 (9%) human subjects' oral flora, and five of 17 (29%) subjects' skin flora.<sup>31,32</sup> Nonetheless, other staphylococcal species are much more common: *S. intermedius* constituted only 23 of 375 staphylococcal isolates from the skin of 17 individuals.<sup>32</sup>

Interestingly, regular contact with animals in and of itself does not appear to increase the rate of colonization. Talan *et al.* only found *S. intermedius* in the nasopharyngeal flora of one out of 144 healthy veterinary workers.<sup>33</sup> Similar studies on *S. pseudintermedius* have detected the methicillin-resistant strain of the organism

Table 2. Antibiotic susceptibilities across cases reviewed.

|                               | Isolates tested | Isolates susceptible (%) |
|-------------------------------|-----------------|--------------------------|
| Aminoglycosides               | 23              | 18 (78%)                 |
| Amikacin                      | 1               | 0 (0%)                   |
| Erythromycin                  | 10              | 7 (70%)                  |
| Gentamicin                    | 10              | 10 (100%)                |
| Kanamycin                     | 1               | 1 (100%)                 |
| Streptomycin                  | 1               | 0 (0%)                   |
| Cephalosporins                | 8               | 5 (63%)                  |
| Cefazolin                     | 7               | 5 (71%)                  |
| Cefotaxime                    | 1               | 0 (0%)                   |
| Glycopeptides                 | 12              | 12 (100%)                |
| Teicoplanin                   | 1               | 1 (100%)                 |
| Vancomycin                    | 11              | 11 (100%)                |
| Lincosamides                  | 10              | 7 (70%)                  |
| Clindamycin                   | 9               | 6 (66%)                  |
| Lincomycin                    | 1               | 1 (100%)                 |
| Penicillins                   | 35              | 22 (63%)                 |
| Amoxicillin-clavulanate       | 4               | 4 (100%)                 |
| Ampicillin-sulbactam          | 5               | 4 (80%)                  |
| Flucloxacillin                | 1               | 1 (100%)                 |
| Methicillin                   | 2               | 1 (50%)                  |
| Oxacillin                     | 10              | 8 (80%)                  |
| Penicillin                    | 13              | 4 (31%)                  |
| Quinolones                    | 14              | 12 (86%)                 |
| Ciprofloxacin                 | 5               | 5 (100%)                 |
| Levofloxacin                  | 7               | 6 (86%)                  |
| Ofloxacin                     | 1               | 0 (0%)                   |
| Pefloxacin                    | 1               | 1 (100%)                 |
| Streptogramins                | 2               | 1 (50%)                  |
| Pristinamycin                 | 1               | 1 (100%)                 |
| Quinupristin/dalfopristin     | 1               | 0 (0%)                   |
| Tetracyclines                 | 9               | 4 (44%)                  |
| Doxycycline                   | 2               | 1 (50%)                  |
| Minocycline                   | 1               | 1 (100%)                 |
| Tetracycline                  | 6               | 2 (33%)                  |
| Other                         |                 |                          |
| Chloramphenicol               | 2               | 2 (100%)                 |
| Colistin                      | 1               | 0 (0%)                   |
| Fosfomycin                    | 1               | 1 (100%)                 |
| Fusidic acid                  | 1               | 1 (100%)                 |
| Linezolid                     | 1               | 1 (100%)                 |
| Mupirocin                     | 1               | 1 (100%)                 |
| Nitrofurantoin                | 3               | 3 (100%)                 |
| Rifampin                      | 3               | 3 (100%)                 |
| Trimethoprim-sulfamathoxazole | 8               | 7 (88%)                  |

Method of susceptibility testing was not reported in 11 of 17 articles reviewed. Reported methods included the automated Vitek system, Phoenix automated system, disc diffusion testing, manual dilution testing. Only two published reports referenced CLSI guidelines.

in 3-5% of samples from owners of pets with recent *S. intermedius* clinical infection and seven of 128 (5%) veterinarians.<sup>34-36</sup> There are data, however, to suggest that transient increases in dogs' bacterial load may increase the risk of transmission to humans. Guardabassi *et al.* found antimicrobial-resistant *S. intermedius* strains in six of 13 dog owners whose pets were being treated for pyoderma.<sup>37</sup> The owners' strains were mostly identical to those found in their dogs. However, *S. intermedius* was no longer present in these same dog owners two months later, suggesting that human acquisition might be transiently related to increased colonization pressure or antibiotic exposure when their pets are acutely ill.

Only three pet-related cases confirmed matching *S. intermedius* strains between patient and dog via pulse field gel electrophoresis and PCR restriction fragment length polymorphism. In two of the cases, the patient reported a history of dog licks at the site of infection. Our patient did not recall any episodes of her dog licking her wound, but transmission could have occurred through direct inoculation of the wound from contact with her dog's skin or indirectly through colonization of the patient followed by invasion of the wound.<sup>3</sup>

Treatment of SIG infections in humans has been largely directed by the site of infection and antibiotic susceptibilities. In the cases reviewed, treatment courses ranged from four days of topical antibiotics for otitis externa to eight weeks of intravenous antibiotics for brain abscess.<sup>14,17</sup> Susceptibility patterns are documented in Table 2. Three reports performed testing for the *mecA* gene, with three of four cases being negative.<sup>15,27,30</sup> Guardabassi *et al.* suggest that pets may facilitate the spread of resistance genes, serving as reservoirs, and resistance patterns in human infections may reflect increasing use of antibiotics in pets.<sup>37</sup> In all except one case, patients had complete recovery after treatment: one individual with a *S. intermedius* brain abscess reported minor residual hemiparesis following antibiotic treatment but no recrudescence infection.<sup>17</sup> Our patient is the first reported case of mechanical prosthesis infection. Despite retention of prosthesis, our patient has been clinically well thus far following six weeks of induction therapy with cefazolin and rifampin followed by 10 months of oral levofloxacin and rifampin to date.

## Conclusions

To the best of our knowledge, this is the first reported human case of mechanical prosthesis infection with a SIG organism, the second reported case of infection in the immediate

post-operative period, and only the fourth case of a SIG post-surgical wound infection. The actual incidence may be higher due to misidentification of *S. intermedius* and *S. pseudintermedius* as *S. aureus*. Immune status does not appear to be a factor in SIG infection, and infections can be monomicrobial or polymicrobial. Overall, infections seem to respond well to therapy guided by susceptibility tests. The possibility of direct transmission of a pathogenic organism from a pet to a post-surgical wound suggests that surgical patients may need to be warned to limit direct contact with pets, particularly dogs, during recovery. However, more studies confirming matching strains between pets and owners are needed to establish direct transmission in the setting of human infection.

## References

- Vandenesch F, Célard M, Arpin D, et al. Catheter-related bacteremia associated with coagulase-positive *Staphylococcus intermedius*. *J Clin Microbiol* 1995;33: 2508-10.
- Boerlin P, Eugster S, Gaschen F, et al. Transmission of opportunistic pathogens in a veterinary teaching hospital. *Vet Microbiol* 2001;82:347-59.
- Biberstein EL, Jang SS, Hirsh DC. Species distribution of coagulase-positive *Staphylococci* in animals. *J Clin Microbiol* 1984; 19:610-5.
- Talan DA, Staats D, Staats A, et al. *Staphylococcus intermedius* in canine gingiva and canine-inflicted human wound infections: laboratory characterization of a newly recognized zoonotic pathogen. *J Clin Microbiol* 1989;27:78-81.
- Douglas LG. Bite wounds. *Am Fam Physician* 1975;11:98-9.
- Feder HM, Shanley JD, Barbera JA. Review of 59 patients hospitalized with animal bites. *Pediatr Infect Dis J* 1987;6:24-8.
- Goldstein EJC. Bite wounds and infection. *Clin Infect Dis* 1992;14:633-8.
- Barnham M, Homes B. Isolation of CDC group M-5 and *Staphylococcus intermedius* from infected dog bites. *J Infect* 1992;25:332-4.
- Talan DA, Goldstein EJ, Staats D, Overturf GD. *Staphylococcus intermedius*: clinical presentation of a new human dog bite pathogen. *Ann Emerg Med* 1989;18:410-3.
- Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. *N Engl J Med* 1999;340:85-92.
- Lee J. *Staphylococcus intermedius* isolated from dog-bite wounds. *J Infect* 1994;29: 105.
- Gerstadt K, Daly JS, Mitchell M, et al. Methicillin-resistant *Staphylococcus intermedius* pneumonia following coronary artery bypass grafting. *Clin Infect Dis* 1999;29:218-9.
- Kempker R, Mangalat D, Kongphet-Tran T, Eaton M. Beware of the pet dog: a case of *Staphylococcus intermedius* infection. *Am J Med Sci* 2009;338:425-7.
- Tanner MA, Everett CL, Youvan DC. Molecular phylogenetic evidence for noninvasive zoonotic transmission of *Staphylococcus intermedius* from a canine pet to a human. *J Clin Microbiol* 2000;38: 1628-31.
- Pottumarthy S, Schapiro JM, Prentice JL, et al. Clinical isolates of *Staphylococcus intermedius* masquerading as methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 2004;42:5881-4.
- Kikuchi K, Karasawa T, Piao C, et al. Molecular confirmation of transmission route of *Staphylococcus intermedius* in mastoid cavity infection from dog saliva. *J Infect Chemother* 2004;10:46-8.
- Atalay B, Ergin F, Cekinmez M, et al. Brain abscess caused by *Staphylococcus intermedius*. *Acta Neurochir* 2005;147:347-8.
- Kelesidis T, Tsiodras S. *Staphylococcus intermedius* is not only a zoonotic pathogen, but may also cause skin abscesses in humans after exposure to saliva. *Int J Infect Dis* 2010;14:e838-41.
- Hatch S, Sree A, Tirrell S, et al. Metastatic complications from *Staphylococcus intermedius*, a zoonotic pathogen. *J Clin Microbiol* 2012;50:1099-101.
- Khambaty F, Bennet R, Shah D. Application of pulse-field gel electrophoresis to the epidemiological characterization of *Staphylococcus intermedius* implicated in a food-related outbreak. *Epidemiol Infect* 1994;113:75-81.
- Devriese LA, Vancanneyt M, Baele M, et al. *Staphylococcus pseudintermedius* sp. nov., a coagulase-positive species from animals. *Int J Syst Evol Microbiol* 2005;55:1569-73.
- Sasaki T, Kikuchi K, Tanaka Y, et al. Reclassification of phenotypically identified *Staphylococcus intermedius* strains. *J Clin Microbiol* 2007;45:2770-8.
- Perreten V, Kadlec K, Schwarz S, et al. Clonal spread of methicillin-resistant *Staphylococcus pseudintermedius* in Europe and North America: an international multicentre study. *J Antimicrob Chemother* 2010;65:1145-54.
- Fitzgerald JR. The *Staphylococcus intermedius* group of bacterial pathogens: species re-classification, pathogenesis and the emergence of methicillin resistance. *Vet Dermatol* 2009;20:490-5.
- Versalovic J, ed. *Manual of clinical microbiology*. 10th ed. Washington, DC: ASM Press; 2011.
- Decristophoris P, Fasola A, Benagli C, et al. Identification of *Staphylococcus intermedius* group by MALDI-TOF MS. *Syst Appl*

- Microbiol 2011;34:45-51.
27. Stegmann R, Burnens A, Maranta C, et al. Human infection associated with methicillin-resistant *Staphylococcus pseudintermedius* ST71. *J Antimicrob Chemo* 2010; 65:2047-8.
  28. Riegel P, Jesel-Morel L, Laventie B, et al. Coagulase-positive *Staphylococcus pseudintermedius* from animals causing human endocarditis. *Int J Med Micro* 2011;301: 237-9.
  29. Chuang C, Yang Y, Huseh P, et al. Catheter-related bacteremia caused by *Staphylococcus pseudintermedius* refractory to antibiotic-lack therapy in a hemophilic child with dog exposure. *J Clin Microbiol* 2010;48:1497-8.
  30. Van Hoovels L, Vankeerberghen A, Boel A, et al. First case of *Staphylococcus pseudintermedius* infection in a human. *J Clin Microbiol* 2006;44:4609-12.
  31. Ohara-Nemoto Y, Haraga H, Kimura S, Nemoto TK. Occurrence of staphylococci in the oral cavities of healthy adults and nasal oral trafficking of the bacteria. *J Med Microbiol* 2008;57:95-9.
  32. Maggs A, Pennington T. Temporal study of staphylococcal species on the skin of human subjects in isolation and clonal analysis of *Staphylococcus capitis* by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. *J Clin Microbiol* 1989;27: 2627-32.
  33. Talan DA, Staats D, Staats A, Overturf GD. Frequency of *Staphylococcus intermedius* as human nasopharyngeal flora. *J Clin Microbiol* 1989;27:2393-4.
  34. Laarhoven LM, de Heus P, van Luijn J, et al. Longitudinal study on methicillin-resistant *Staphylococcus pseudintermedius* in households. *PLoS One* 2011;6:e27788.
  35. Van Duijkeren E, Kamphuis M, van der Mije, IC et al. Transmission of methicillin-resistant *Staphylococcus pseudintermedius* between infected dogs and cats and contact pets, humans and the environment in households and veterinary clinics. *Vet Microbiol* 2011;150:338-43.
  36. Paul NC, Moodley A, Ghibaud G, Guardabassi L. Carriage of methicillin-resistant *Staphylococcus pseudintermedius* in small animal veterinarians: indirect evidence of zoonotic transmission. *Zoonoses Public Health* 2011;58:533-9.
  37. Guardabassi L, Loeber M, Jacobson A. Transmission of multiple antimicrobial-resistant *Staphylococcus intermedius* between dogs affected by deep pyoderma and their owners. *Vet Microbiol* 2004; 98:23-7.